There are contradictory results regarding the association between angiotensin-converting enzyme (ACE) inhibitors and cancer.
Dr Tomas Sjöberg and colleagues from the United Kingdom investigated whether angiotensin-converting enzyme-inhibitors protect against esophageal and gastric cancer.
|A high daily dose decreased total esophageal cancer by 45%|
|Clinical Gastroenterology and Hepatology|
The team conducted a population-based case-control study nested within the General Practitioners' Research Database in the United Kingdom.
All individuals in the General Practitioners' Research Database aged 40 to 84 years between 1994 and 2001 were assessed.
The patients were followed up until detection of an esophageal or gastric cancer, other cancer, age of 85 years, death, or end of study period.
The researchers identified 909 cases of esophageal and 1023 cases of gastric cancer.
The research team also randomly selected 10,000 matched controls.
Adjustments included smoking, body mass index, concurrent medication, and gastrointestinal disorders.
The team found that current use of angiotensin-converting enzyme inhibitors decreased the risk of esophageal adenocarcinoma by 29% compared with nonusers.
However, the risk of squamous-cell carcinoma was not reduced compared with nonusers.
A high daily dose of angiotensin-converting enzyme inhibitors decreased the risk of both adenocarcinoma and squamous-cell cancer of the oesophagus.
The research team found that a high daily dose rendered a 45% decrease of total esophageal cancer.
The team showed no clear association between the use of angiotensin-converting enzyme inhibitors and risk of gastric cancer.
Dr Sjöberg's team concluded, "The use of angiotensin-converting enzyme inhibitors may decrease the risk of developing esophageal cancer, particularly among users with a high daily dose."
"No association was found between gastric cancer and angiotensin-converting enzyme inhibitors."